// App-Quantinova.ai

9584 : Treatment-specific risks of second malignancy and cardiovascular disease in Hodgkin lymphoma survivors.

Researchers

Presenter

  • Simone de Vries

Principal Investigators

  • Frederika A. van Nimwegen

  • Judith M. Roesink

  • John M. M. Raemaekers

  • Berthe M.P. Aleman

  • Flora Van Leeuwen

Medical Centers

  • Department of Psychosocial Oncology and Epidemiology, The Netherlands Cancer Institute, Amsterdam, Netherlands

  • Department of Psychosocial Oncology and Epidemiology, The Netherlands Cancer Institute, Amsterdam, NetherlandsLeiden University Medical Center, Department of Clinical Oncology, Leiden, NetherlandsDepartment of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands

  • Department of Hematology, Erasmus MC Cancer Insitute, Rotterdam, Netherlands

  • Department of Urology, Radboud University Medical Center, Nijmegen, Netherlands

  • Department of Pathology, the Netherlands Cancer Institute, Amsterdam, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Congestive heart failure

  • Cardiac valvular dysplasia X-linked

  • Coronary Artery Disease

  • Hodgkin's Lymphoma

  • Heart muscle disease

  • Lymphomas

  • Solid malignancies

  • Systemic inflammatory response syndrome

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved